Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result Spotlight
Bladder and urothelial cancer
Cretostimogene grenadenorepvec (RB–E2F–selective oncolytic virus) drives 75% CR with near-zero severe toxicity in BCG-unresponsive CIS NMIBC
Cretostimogene grenadenorepvec is an intravesical, replication-competent oncolytic immunotherapy that preferentially replicates in and lyses tumor cells with retinoblastoma–E2F pathway alterations while also boosting…
NCT04452591 - Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) lifts EFS/OS vs cisplatin-gemcitabine in MIBC
Enfortumab vedotin is a Nectin-4–directed antibody–drug conjugate (MMAE payload) and pembrolizumab is a PD-1 inhibitor; in the Phase 3, open-label KEYNOTE-B15/EV-304 trial (NCT04700124), cisplatin-eligible…
NCT04700124 - Trial result Spotlight
Thyroid cancer
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer
Dabrafenib, a BRAF inhibitor, plus the MEK inhibitor trametinib was tested in a global, randomized, double-blind Phase 3 trial (NCT04940052) in previously treated, radioactive iodine–refractory BRAF V600E–positive…
NCT04940052 - Trial result
Thyroid cancer
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status
Atezolizumab is an anti–PD-L1 checkpoint inhibitor combined here with MAPK-pathway targeted therapy—BRAF V600E patients received vemurafenib (BRAF inhibitor) + cobimetinib (MEK inhibitor), while RAS/NF-mutant…
NCT03181100 - Trial result
Liver and bile duct cancer
Rucaparib (PARP inhibitor) + nivolumab (PD-1) maintenance misses primary PFS bar in advanced BTC, with signal in DDR/IDH1 subsets
Rucaparib is an oral PARP inhibitor paired here with nivolumab, a PD-1 antibody, as switch-maintenance after 4-6 months of first-line platinum chemotherapy in advanced biliary tract cancer (BilT-02; Phase 2,…
NCT03639935 - Trial result
Colorectal cancer
Vactosertib (TGFBR1/ALK5 inhibitor) + pembrolizumab drives 12.6% ORR in MSS/non–MSI-high mCRC—0% in gastric cancer
Vactosertib is an oral TGF-β receptor type 1 (TGFBR1/ALK5) kinase inhibitor designed to blunt TGF-β–mediated immune exclusion, and was combined with pembrolizumab (PD-1) in a multicenter, open-label, single-arm Phase…
NCT03724851 - Trial result
Colorectal cancer
Ad5.F35-GUCY2C-PADRE (adenoviral vaccine swapping Ad35 fiber) drives CD8+ immunity and fewer CRC recurrences
Ad5.F35-GUCY2C-PADRE is a chimeric adenovirus serotype 5 vaccine expressing the intestinal tumor antigen GUCY2C (plus PADRE helper epitope) and using an Ad35 fiber to bypass pre-existing anti-Ad5 neutralizing…
NCT04111172 - Trial result
Colorectal cancer
Doublet long-course TNT (capecitabine/oxaliplatin) improves DFS and pCR vs standard nCRT in high-risk LARC
Doublet-LC TNT integrates long-course radiotherapy (LCRT) with uninterrupted doublet chemotherapy (capecitabine + oxaliplatin; induction → concurrent → consolidation) before surgery, versus conventional neoadjuvant…
NCT03177382 - Trial result
Other blood cancers and transplant
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden
Post-transplant cyclophosphamide (PTCy), followed by tacrolimus and mycophenolate, was used for graft-versus-host disease prophylaxis in the multicenter Phase 2 ACCESS trial (NCT04904588) of mismatched…
NCT04904588 - Trial result Spotlight
Multiple solid tumors
Erdafitinib (pan-FGFR TKI) drives 56% ORR in FGFR-altered pancreatic cancer in RAGNAR
Erdafitinib is an oral pan-FGFR1–4 tyrosine kinase inhibitor (TKI) tested in the Phase 2, histology-agnostic RAGNAR trial (NCT04083976) in patients with advanced/unresectable/metastatic solid tumors and FGFR…
NCT04083976 - Trial result
Multiple solid tumors
CS2009 PD-1/VEGF/CTLA-4 trispecific posts 18.5% ORR in heavily pretreated NSCLC (no actionable drivers)
CS2009 is a first-in-class trispecific antibody designed to simultaneously block PD-1 and CTLA-4 immune checkpoints while neutralizing VEGF (anti-angiogenesis), evaluated in an open-label, multicenter Phase 1…
NCT06741644 - New trial Spotlight
Ovarian cancer
Phase 3 rinatabart sesutecan (Rina-S) FRα ADC delivering exatecan (topoisomerase I inhibitor)
Genmab’s open-label, randomized Phase 3 trial (NCT07564141; ~688 participants planned) tests rinatabart sesutecan (Rina-S)—a folate receptor alpha (FRα/FOLR1)–directed antibody-drug conjugate that delivers an…
NCT07564141 Registrational - New trial
Ovarian cancer
Phase 1 NTB-928 FRα×CD3 bispecific T-cell engager in relapsed/refractory ovarian carcinoma.
This Phase 1, multicenter, open-label dose-escalation and expansion study tests NTB-928, a fully human FRα (FOLR1)×CD3 bispecific T-cell engager antibody that redirects T cells to kill FRα-overexpressing tumor cells.…
NCT07690189 First-in-human - New trial Spotlight
Cervical and other gynecologic cancers
Phase 2 tisotumab vedotin (tissue factor–targeted) MMAE ADC in recurrent/metastatic vulvar SCC.
This open-label, single-arm Phase 2 study sponsored by the GOG Foundation evaluates tisotumab vedotin in recurrent or metastatic vulvar squamous cell carcinoma, with objective response rate as the primary efficacy…
NCT07672782 Exploratory - New trial
Sarcoma and GIST
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma.
This multicenter, open-label, cohort-sequential Phase 1/2 trial tests domatinostat plus sirolimus in adolescents and adults with relapsed/refractory sarcoma (Phase 1 dose escalation) and relapsed/refractory…
NCT07725380 Exploratory - New trial
Head and neck cancer
Phase 2 64Cu-DOTA-ECL1i CCR2-targeted PET radiotracer imaging in HNSCC.
This prospective, two-cohort precision-imaging study at Washington University School of Medicine evaluates whether 64Cu-DOTA-ECL1i PET/CT—a copper-64–labeled peptide radiotracer that binds CCR2 (C-C chemokine…
NCT07659678 Exploratory - New trial
Head and neck cancer
Phase 1/2 SX-682 CXCR1/2 inhibitor plus docetaxel microtubule inhibitor in R/M HNSCC
This National Cancer Institute (NCI) Phase 1/2 study tests SX-682, an oral small-molecule CXCR1/CXCR2 inhibitor designed to block IL-8–axis chemokine signaling that recruits pro-tumor myeloid cells, in combination…
NCT07667400 Exploratory - New trial
Multiple solid tumors
Phase 1/2 N17350 intratumoral ELANE-pathway therapeutic elastase (recombinant mutant elastase)
This Phase 1/2 open-label, dose-finding and expansion study (OP-NEU-101) tests intratumoral N17350 injections every 2 weeks (typically up to 12 weeks) in adults with advanced/metastatic solid tumors that have…
NCT07339176 First-in-human - New trial
Multiple solid tumors
Phase 1/2a VBC106 FRα/MSLN-targeted topo1 inhibitor antibody-drug conjugate in solid tumors.
This first-in-human, multicenter, open-label Phase 1/2a study from VelaVigo Bio evaluates VBC106, an FRα (FOLR1)- and mesothelin (MSLN)-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor…
NCT07686068 First-in-human - New trial
Multiple solid tumors
Phase 1/2 TORL-5-700 ADC; target/MOA not publicly disclosed (first-in-human)
No disclosed MOA. We do not include details of trials without this basic information.
NCT07439653 First-in-human - Trial result Spotlight
Acute lymphoblastic leukemia
Memory-enriched CD19 CAR-T delivers 84% 18-mo EFS in older CR1 B-ALL
Memory-enriched autologous CD19 CAR-T cells are engineered to target CD19 and were tested as “definitive consolidation” after remission rather than as salvage therapy. In a Phase 1 study in older adults with B-cell…
NCT05707273 - Trial result
Acute lymphoblastic leukemia
Ixazomib (MLN9708) Proteasome Inhibitor + Salvage Chemo Delivers 67% CR in Pediatric R/R ALL
Ixazomib is an oral proteasome inhibitor (more potent than bortezomib preclinically; FDA-approved in multiple myeloma) evaluated in a TACL Phase 1/2, 3+3 dose-escalation study combining ixazomib with established…
NCT03817320 - Trial result
Other blood cancers and transplant
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL
Vemurafenib is an oral BRAF inhibitor (active in BRAF V600E–mutant classic HCL) and rituximab is an anti-CD20 monoclonal antibody; in this prospective observational “Scripps regimen” study, patients received…
NCT05388123 - Trial result Spotlight
Chronic lymphocytic leukemia
Pirtobrutinib (non-covalent BTK inhibitor) + venetoclax-rituximab lifts PFS vs VR in relapsed CLL/SLL
Pirtobrutinib (LOXO-305; a reversible/non-covalent BTK inhibitor) was added to fixed-duration venetoclax (BCL2 inhibitor) + rituximab (anti-CD20) in BRUIN CLL-322, an open-label, randomized Phase 3 trial in…
NCT04965493 - Trial result
Chronic lymphocytic leukemia
SAVE: Obinutuzumab + venetoclax (BCL-2 inhibitor) compresses the 5-week ramp-up to 7 inpatient days with 0 clinical TLS
In the Phase Ib SAVE study (NCT04843904), venetoclax (VEN), an oral BCL-2 inhibitor, was initiated with an accelerated *daily* inpatient ramp-up (20→400mg) in CLL, almost universally combined with the anti-CD20…
NCT04843904 - Trial result
Chronic lymphocytic leukemia
BOVen (zanubrutinib BTK inhibitor + venetoclax BCL2 inhibitor + obinutuzumab anti-CD20) delivers 92% blood+marrow uMRD4 with ~80% 4-year PFS in frontline CLL
BOVen combines zanubrutinib (covalent BTK inhibitor), venetoclax (BCL2 inhibitor), and obinutuzumab (type II anti-CD20 mAb) as an MRD-driven, time-limited triplet in a multicentre, single-arm Phase 2 frontline…
NCT03824483 - Trial result
Acute myeloid leukemia and MDS
Venetoclax (BCL-2 inhibitor) + high-dose cytarabine drives 57% CR/CRi in pediatric R/R AML (VENAML)
VENAML tested venetoclax, an oral BCL-2 inhibitor that restores mitochondrial apoptosis priming, combined with high-dose cytarabine (± idarubicin/dexrazoxane or azacitidine) in a multicentre Phase 1 expansion in…
NCT03194932 - Trial result Spotlight
Chronic myeloid leukemia
Asciminib deepens frontline molecular responses in East Asian CML-CP subgroup
Asciminib is a first-in-class allosteric BCR–ABL1 inhibitor that binds the ABL myristoyl pocket rather than the ATP-binding site targeted by standard TKIs. In the East Asian subgroup of the Phase 3 ASC4FIRST trial in…
NCT04971226 - Trial result
Brain and CNS tumors
Pembrolizumab + HSPPC-96 misses 1-year OS endpoint in newly diagnosed GBM
Pembrolizumab is an anti–PD-1 antibody, and HSPPC-96 is a personalized tumor-derived HSP96-peptide vaccine designed to broaden antigen presentation. In a multi-institutional Phase 2 randomized, placebo-controlled…
NCT03018288 - Trial result
Brain and CNS tumors
WT1/PRAME/survivin trivalent TAA‑T cells show tolerable safety and rare long remissions in pediatric CNS tumors
ReMIND (NCT03652545) tested autologous, non–gene-engineered multi-antigen tumor-associated antigen–specific T cells (TAA‑Ts) targeting intracellular WT1, PRAME, and survivin, given systemically in an open-label Phase…
NCT03652545
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.